253 related articles for article (PubMed ID: 35074498)
1. PKC agonism restricts innate immune suppression, promotes antigen cross-presentation and synergizes with agonistic CD40 antibody therapy to activate CD8
Chaib M; Sipe LM; Yarbro JR; Bohm MS; Counts BR; Tanveer U; Pingili AK; Daria D; Marion TN; Carson JA; Thomas PG; Makowski L
Cancer Lett; 2022 Apr; 531():98-108. PubMed ID: 35074498
[TBL] [Abstract][Full Text] [Related]
2. Bispecific antibodies targeting CD40 and tumor-associated antigens promote cross-priming of T cells resulting in an antitumor response superior to monospecific antibodies.
Hägerbrand K; Varas L; Deronic A; Nyesiga B; Sundstedt A; Ljung L; Sakellariou C; Werchau D; Thagesson M; Gomez Jimenez D; Greiff L; Celander M; Smedenfors K; Rosén A; Bölükbas D; Carlsson F; Levin M; Säll A; von Schantz L; Lindstedt M; Ellmark P
J Immunother Cancer; 2022 Nov; 10(11):. PubMed ID: 36323431
[TBL] [Abstract][Full Text] [Related]
3. cDC1 prime and are licensed by CD4
Ferris ST; Durai V; Wu R; Theisen DJ; Ward JP; Bern MD; Davidson JT; Bagadia P; Liu T; Briseño CG; Li L; Gillanders WE; Wu GF; Yokoyama WM; Murphy TL; Schreiber RD; Murphy KM
Nature; 2020 Aug; 584(7822):624-629. PubMed ID: 32788723
[TBL] [Abstract][Full Text] [Related]
4. Anti-CD40 Antibody Fused to CD40 Ligand Is a Superagonist Platform for Adjuvant Intrinsic DC-Targeting Vaccines.
Ceglia V; Zurawski S; Montes M; Kroll M; Bouteau A; Wang Z; Ellis J; Igyártó BZ; Lévy Y; Zurawski G
Front Immunol; 2021; 12():786144. PubMed ID: 35095862
[TBL] [Abstract][Full Text] [Related]
5. Activation of dendritic cells that cross-present tumor-derived antigen licenses CD8+ CTL to cause tumor eradication.
van Mierlo GJ; Boonman ZF; Dumortier HM; den Boer AT; Fransen MF; Nouta J; van der Voort EI; Offringa R; Toes RE; Melief CJ
J Immunol; 2004 Dec; 173(11):6753-9. PubMed ID: 15557168
[TBL] [Abstract][Full Text] [Related]
6. Sunitinib enhances the antitumor responses of agonistic CD40-antibody by reducing MDSCs and synergistically improving endothelial activation and T-cell recruitment.
van Hooren L; Georganaki M; Huang H; Mangsbo SM; Dimberg A
Oncotarget; 2016 Jul; 7(31):50277-50289. PubMed ID: 27385210
[TBL] [Abstract][Full Text] [Related]
7. Dendritic cells require NIK for CD40-dependent cross-priming of CD8+ T cells.
Katakam AK; Brightbill H; Franci C; Kung C; Nunez V; Jones C; Peng I; Jeet S; Wu LC; Mellman I; Delamarre L; Austin CD
Proc Natl Acad Sci U S A; 2015 Nov; 112(47):14664-9. PubMed ID: 26561586
[TBL] [Abstract][Full Text] [Related]
8. The tumor-targeted CD40 agonist CEA-CD40 promotes T cell priming via a dual mode of action by increasing antigen delivery to dendritic cells and enhancing their activation.
Sum E; Rapp M; Dürr H; Mazumdar A; Romero PJ; Trumpfheller C; Umaña P
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35292514
[TBL] [Abstract][Full Text] [Related]
9. Functional Specialty of CD40 and Dendritic Cell Surface Lectins for Exogenous Antigen Presentation to CD8(+) and CD4(+) T Cells.
Yin W; Gorvel L; Zurawski S; Li D; Ni L; Duluc D; Upchurch K; Kim J; Gu C; Ouedraogo R; Wang Z; Xue Y; Joo H; Gorvel JP; Zurawski G; Oh S
EBioMedicine; 2016 Mar; 5():46-58. PubMed ID: 27077111
[TBL] [Abstract][Full Text] [Related]
10. Cross-priming CD8+ T cells by targeting antigens to human dendritic cells through DCIR.
Klechevsky E; Flamar AL; Cao Y; Blanck JP; Liu M; O'Bar A; Agouna-Deciat O; Klucar P; Thompson-Snipes L; Zurawski S; Reiter Y; Palucka AK; Zurawski G; Banchereau J
Blood; 2010 Sep; 116(10):1685-97. PubMed ID: 20530286
[TBL] [Abstract][Full Text] [Related]
11. Effective cancer immunotherapy by natural mouse conventional type-1 dendritic cells bearing dead tumor antigen.
Wculek SK; Amores-Iniesta J; Conde-Garrosa R; Khouili SC; Melero I; Sancho D
J Immunother Cancer; 2019 Apr; 7(1):100. PubMed ID: 30961656
[TBL] [Abstract][Full Text] [Related]
12. Dendritic cell targeting with Fc-enhanced CD40 antibody agonists induces durable antitumor immunity in humanized mouse models of bladder cancer.
Garris CS; Wong JL; Ravetch JV; Knorr DA
Sci Transl Med; 2021 May; 13(594):. PubMed ID: 34011627
[TBL] [Abstract][Full Text] [Related]
13. Distinct myeloid antigen-presenting cells dictate differential fates of tumor-specific CD8+ T cells in pancreatic cancer.
Burrack AL; Schmiechen ZC; Patterson MT; Miller EA; Spartz EJ; Rollins MR; Raynor JF; Mitchell JS; Kaisho T; Fife BT; Stromnes IM
JCI Insight; 2022 Apr; 7(7):. PubMed ID: 35393950
[TBL] [Abstract][Full Text] [Related]
14. Combined triggering of dendritic cell receptors results in synergistic activation and potent cytotoxic immunity.
Wells JW; Cowled CJ; Farzaneh F; Noble A
J Immunol; 2008 Sep; 181(5):3422-31. PubMed ID: 18714014
[TBL] [Abstract][Full Text] [Related]
15. In vivo ligation of CD40 enhances priming against the endogenous tumor antigen and promotes CD8+ T cell effector function in SV40 T antigen transgenic mice.
Staveley-O'Carroll K; Schell TD; Jimenez M; Mylin LM; Tevethia MJ; Schoenberger SP; Tevethia SS
J Immunol; 2003 Jul; 171(2):697-707. PubMed ID: 12847236
[TBL] [Abstract][Full Text] [Related]
16. β-catenin mediates tumor-induced immunosuppression by inhibiting cross-priming of CD8⁺ T cells.
Liang X; Fu C; Cui W; Ober-Blöbaum JL; Zahner SP; Shrikant PA; Clausen BE; Flavell RA; Mellman I; Jiang A
J Leukoc Biol; 2014 Jan; 95(1):179-90. PubMed ID: 24023259
[TBL] [Abstract][Full Text] [Related]
17. Vaccination against neoantigens induced in cross-priming cDC1 in vivo.
Clark ES; Benaduce AP; Khan WN; Martinez O; Gilboa E
Cancer Immunol Immunother; 2024 Jan; 73(1):9. PubMed ID: 38231450
[TBL] [Abstract][Full Text] [Related]
18. Multimodal Intralesional Therapy for Reshaping the Myeloid Compartment of Tumors Resistant to Anti-PD-L1 Therapy via IRF8 Expression.
Patel A; Oba T; Kajihara R; Yokoi T; Abrams SI; Ito F
J Immunol; 2021 Sep; 207(5):1298-1309. PubMed ID: 34362833
[TBL] [Abstract][Full Text] [Related]
19. Regulatory T cells and myeloid-derived suppressor cells in the tumor microenvironment undergo Fas-dependent cell death during IL-2/αCD40 therapy.
Weiss JM; Subleski JJ; Back T; Chen X; Watkins SK; Yagita H; Sayers TJ; Murphy WJ; Wiltrout RH
J Immunol; 2014 Jun; 192(12):5821-9. PubMed ID: 24808361
[TBL] [Abstract][Full Text] [Related]
20. Lipopolysaccharide modulation of dendritic cells is insufficient to mature dendritic cells to generate CTLs from naive polyclonal CD8+ T cells in vitro, whereas CD40 ligation is essential.
Kelleher M; Beverley PC
J Immunol; 2001 Dec; 167(11):6247-55. PubMed ID: 11714787
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]